Control of mitogenic and motogenic pathways by miR-198, diminishing hepatoma cell growth and migration

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 5, 2013, Pages 1190-1198

  Elfimova, Natalia ^a   Sievers, Elisabeth ^a   Eischeid, Hannah ^a   Kwiecinski, Monika ^a   Noetel, Andrea ^a   Hunt, Heike ^b   Becker, Diana ^c   Frommolt, Peter ^d,e   Quasdorff, Maria ^a   Steffen, Hans Michael ^a   Nürnberg, Peter ^d,e   Büttner, Reinhard ^a   Teufel, Andreas ^c   Dienes, Hans Peter ^a   Drebber, Uta ^a   Odenthal, Margarete ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cell migration; Cell proliferation and apoptosis; Claudin 1; Expression profiles; Hepatocellular carcinoma; MiRNA

Indexed keywords

CLAUDIN 1; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; MICRORNA; MICRORNA 198; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER GROWTH; CELL ADHESION; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIMIT OF QUANTITATION; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

CADHERINS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CLAUDIN-1; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HEPATOCYTE NUCLEAR FACTOR 4; HUMANS; MICRORNAS;

EID: 84874722296     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.01.023     Document Type: Article

References (48)

1. Breuhahn K., Gores G., Schirmacher P. Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. Hepatology (Baltimore, Md) 2011, 53:2112-2121.
2. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
3. Thorgeirsson S.S., Lee J.S., Grisham J.W. Functional genomics of hepatocellular carcinoma. Hepatology 2006, 43:S145-S150.
4. Breuhahn K., Longerich T., Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006, 25:3787-3800.
5. Roskams T., Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Sem. Liver Dis. 2010, 30:17-25.
6. Kondoh N., Wakatsuki T., Hada A., Shuda M., Tanaka K., Arai M., Yamamoto M. Genetic and epigenetic events in human hepatocarcinogenesis. Int. J. Oncol. 2001, 18:1271-1278.
7. Hoshida Y., Toffanin S., Lachenmayer A., Villanueva A., Minguez B., Llovet J.M. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Sem. Liver Dis. 2010, 30:35-51.
8. Breuhahn K., Schirmacher P. Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World J. Gastroenterol. 2008, 14:1690-1698.
9. Kaposi-Novak P., Lee J.S., Gomez-Quiroz L., Coulouarn C., Factor V.M., Thorgeirsson S.S. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest. 2006, 116:1582-1595.
10. Horiguchi N., Takayama H., Toyoda M., Otsuka T., Fukusato T., Merlino G., Takagi H., Mori M. Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene 2002, 21:1791-1799.
11. Ueki T., Fujimoto J., Suzuki T., Yamamoto H., Okamoto E. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 1997, 25:862-866.
12. Kumar A. MicroRNA in HCV infection and liver cancer. Biochim. Biophys. Acta 2011, 1809:694-699.
13. Braconi C., Henry J.C., Kogure T., Schmittgen T., Patel T. The role of microRNAs in human liver cancers. Semin. Oncol. 2011, 38:752-763.
14. Negrini M., Gramantieri L., Sabbioni S., Croce C.M. microRNA involvement in hepatocellular carcinoma. Anti Cancer Agents Med. Chem. 2011, 11:500-521.
15. Ladeiro Y., Couchy G., Balabaud C., Bioulac-Sage P., Pelletier L., Rebouissou S., Zucman-Rossi J. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008, 47:1955-1963.
16. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
17. Pineau P., Volinia S., McJunkin K., Marchio A., Battiston C., Terris B., Mazzaferro V., Lowe S.W., Croce C.M., Dejean A. miR-221 overexpression contributes to liver tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:264-269.
18. Fornari F., Gramantieri L., Ferracin M., Veronese A., Sabbioni S., Calin G.A., Grazi G.L., Giovannini C., Croce C.M., Bolondi L., Negrini M. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008, 27:5651-5661.
19. Gramantieri L., Fornari F., Ferracin M., Veronese A., Sabbioni S., Calin G.A., Grazi G.L., Croce C.M., Bolondi L., Negrini M. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin. Cancer Res. 2009, 15:5073-5081.
20. Varnholt H., Drebber U., Schulze F., Wedemeyer I., Schirmacher P., Dienes H.P., Odenthal M. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008, 47:1223-1232.
21. Jopling C. Liver-specific microRNA-122: biogenesis and function. RNA Biol. 2012, 9.
22. Coulouarn C., Factor V.M., Andersen J.B., Durkin M.E., Thorgeirsson S.S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009, 28:3526-3536.
23. Fornari F., Gramantieri L., Giovannini C., Veronese A., Ferracin M., Sabbioni S., Calin G.A., Grazi G.L., Croce C.M., Tavolari S., Chieco P., Negrini M., Bolondi L. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2009, 69:5761-5767.
24. Girard M., Jacquemin E., Munnich A., Lyonnet S., Henrion-Caude A. miR-122, a paradigm for the role of microRNAs in the liver. J. Hepatol. 2008, 48:648-656.
25. Gao P., Wong C.C., Tung E.K., Lee J.M., Wong C.M., Ng I.O. Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J. Hepatol. 2011, 54:1177-1184.
26. Cheung O., Puri P., Eicken C., Contos M.J., Mirshahi F., Maher J.W., Kellum J.M., Min H., Luketic V.A., Sanyal A.J. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008, 48:1810-1820.
27. Sung T.L., Rice A.P. miR-198 inhibits HIV-1 gene expression and replication in monocytes and its mechanism of action appears to involve repression of cyclin T1. PloS Pathog. 2009, 5:e1000263.
28. Tan S., Li R., Ding K., Lobie P.E., Zhu T. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett. 2011, 585:2229-2234.
29. Nakabayashi H., Taketa K., Yamane T., Miyazaki M., Miyano K., Sato J. Phenotypical stability of a human hepatoma cell line, HuH-7, in long-term culture with chemically defined medium. Gann 1984, 75:151-158.
30. Aden D.P., Fogel A., Plotkin S., Damjanov I., Knowles B.B. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 1979, 282:615-616.
31. Quasdorff M., Hosel M., Odenthal M., Zedler U., Bohne F., Gripon P., Dienes H.P., Drebber U., Stippel D., Goeser T., Protzer U. A concerted action of HNF4alpha and HNF1alpha links hepatitis B virus replication to hepatocyte differentiation. Cell. Microbiol. 2008, 10:1478-1490.
32. Fransvea E., Angelotti U., Antonaci S., Giannelli G. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 2008, 47:1557-1566.
33. Liu J., Lian Z., Han S., Waye M.M., Wang H., Wu M.C., Wu K., Ding J., Arbuthnot P., Kew M., Fan D., Feitelson M.A. Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma. Oncogene 2006, 25:1008-1017.
34. Matsumura T., Makino R., Mitamura K. Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas. Clin. Cancer Res. 2001, 7:594-599.
35. Higashi Y., Suzuki S., Sakaguchi T., Nakamura T., Baba S., Reinecker H.C., Nakamura S., Konno H. Loss of claudin-1 expression correlates with malignancy of hepatocellular carcinoma. J. Surg. Res. 2007, 139:68-76.
36. Liang L., Wong C.M., Ying Q., Fan D.N., Huang S., Ding J., Yao J., Yan M., Li J., Yao M., Ng I.O., He X. MicroRNA-125b suppressed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology 2010, 52:1731-1740.
37. Wang C.M., Wang Y., Fan C.G., Xu F.F., Sun W.S., Liu Y.G., Jia J.H. miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2011, 411:586-592.
38. Lee I., Ajay S.S., Yook J.I., Kim H.S., Hong S.H., Kim N.H., Dhanasekaran S.M., Chinnaiyan A.M., Athey B.D. New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites. Genome Res. 2009, 19:1175-1183.
39. Xu Z., Shen M.X., Ma D.Z., Wang L.Y., Zha X.L. TGF-beta1-promoted epithelial-to-mesenchymal transformation and cell adhesion contribute to TGF-beta1-enhanced cell migration in SMMC-7721 cells. Cell Res. 2003, 13:343-350.
40. Lal-Nag M., Morin P.J. The claudins. Genome Biol. 2009, 10:235.
41. Escudero-Esparza A., Jiang W.G., Martin T.A. The claudin family and its role in cancer and metastasis. Front. Biosci. 2011, 16:1069-1083.
42. Lu Z., Ding L., Hong H., Hoggard J., Lu Q., Chen Y.H. Claudin-7 inhibits human lung cancer cell migration and invasion through ERK/MAPK signaling pathway. Exp. Cell Res. 2011, 317:1935-1946.
43. Ikari A., Sato T., Takiguchi A., Atomi K., Yamazaki Y., Sugatani J. Claudin-2 knockdown decreases matrix metalloproteinase-9 activity and cell migration via suppression of nuclear Sp1 in A549 cells. Life Sci. 2011, 88:628-633.
44. Zavala-Zendejas V.E., Torres-Martinez A.C., Salas-Morales B., Fortoul T.I., Montano L.F., Rendon-Huerta E.P. Claudin-6, 7, or 9 overexpression in the human gastric adenocarcinoma cell line AGS increases its invasiveness, migration, and proliferation rate. Cancer Invest. 2011, 29:1-11.
45. Yoon C.H., Kim M.J., Park M.J., Park I.C., Hwang S.G., An S., Choi Y.H., Yoon G., Lee S.J. Claudin-1 acts through c-Abl-protein kinase Cdelta (PKCdelta) signaling and has a causal role in the acquisition of invasive capacity in human liver cells. J. Biol. Chem. 2010, 285:226-233.
46. K. Hur, Y. Toiyama, M. Takahashi, F. Balaguer, T. Nagasaka, J. Koike, H. Hemmi, M. Koi, C.R. Boland, A. Goel, MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis, Gut (in press), [Electronic publication ahead of print June 2012]. http://dx.doi.org/10.1136/gutjnl-2011-301846.
47. Silvestris N., Tommasi S., Petriella D., Santini D., Fistola E., Russo A., Numico G., Tonini G., Maiello E., Colucci G. The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma. Oncology 2009, 77(Suppl. 1):69-74.
48. Samuels Y., Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr. Top. Microbiol. Immunol. 2010, 347:21-41.